Updated Jul 16, 2026
GUGGENHIME ANDREW has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $7.35M.
Andrew Guggenhime is the President and CFO of Vaxcyte, Inc., a clinical-stage vaccine innovation company focused on developing vaccines for bacterial diseases. He has been involved in multiple SEC filings related to his role at the company.
| Role | PRESIDENT AND CFO |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-06 | PCVX | Vaxcyte, Inc. | S — Open-market sale | 2.1K | $57.76 | $121K |
| 2026-07-06 | PCVX | Vaxcyte, Inc. | S — Open-market sale | 7.9K | $57.16 | $452K |
| 2026-07-06 | PCVX | Vaxcyte, Inc. | M — Option exercise | 10.0K | $5.35 | $54K |
| 2026-06-19 | PCVX | Vaxcyte, Inc. | S — Open-market sale | 10.0K | $53.00 | $530K |
| 2026-06-19 | PCVX | Vaxcyte, Inc. | M — Option exercise | 10.0K | $5.35 | $54K |
| 2026-03-11 | PCVX | Vaxcyte, Inc. | F — Tax withholding / forfeiture | 1.0K | $59.32 | $61K |
| 2026-03-03 | PCVX | Vaxcyte, Inc. | F — Tax withholding / forfeiture | 1.0K | $61.98 | $63K |
| 2026-03-03 | PCVX | Vaxcyte, Inc. | F — Tax withholding / forfeiture | 898 | $61.98 | $56K |
| 2026-03-03 | PCVX | Vaxcyte, Inc. | A — Grant or award | 44.9K | $0.00 | |
| 2026-01-16 | PCVX | Vaxcyte, Inc. | G — Bona-fide gift | 61.9K | $0.00 | |
| 2026-01-16 | PCVX | Vaxcyte, Inc. | G — Bona-fide gift | 61.9K | $0.00 | |
| 2025-09-08 | PCVX | Vaxcyte, Inc. | F — Tax withholding / forfeiture | 2.9K | $32.41 | $94K |
| 2025-09-02 | PCVX | Vaxcyte, Inc. | F — Tax withholding / forfeiture | 1.4K | $31.56 | $45K |
| 2025-09-02 | PCVX | Vaxcyte, Inc. | F — Tax withholding / forfeiture | 2.4K | $31.56 | $75K |
| 2025-09-02 | PCVX | Vaxcyte, Inc. | F — Tax withholding / forfeiture | 1.3K | $31.56 | $40K |
| 2025-04-07 | PCVX | Vaxcyte, Inc. | M — Option exercise | 4.8K | $20.93 | $100K |
| 2024-12-19 | PCVX | Vaxcyte, Inc. | S — Open-market sale [10b5-1] | 280 | $90.24 | $25K |
| 2024-12-19 | PCVX | Vaxcyte, Inc. | S — Open-market sale [10b5-1] | 3.2K | $89.31 | $282K |
| 2024-12-19 | PCVX | Vaxcyte, Inc. | S — Open-market sale [10b5-1] | 3.4K | $88.70 | $299K |
| 2024-12-19 | PCVX | Vaxcyte, Inc. | S — Open-market sale [10b5-1] | 1.2K | $87.26 | $104K |
Andrew Guggenhime is the President and CFO of Vaxcyte, Inc., a clinical-stage vaccine innovation company focused on developing vaccines for bacterial diseases. He has been involved in multiple SEC filings related to his role at the company.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 12 open-market sales ($7.35M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live GUGGENHIME ANDREW profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.